Drug Profile
Emricasan - Histogen
Alternative Names: IDN-6556; PF-03491390; PF-3,491,390; VAY 785Latest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Idun Pharmaceuticals
- Developer Conatus Pharmaceuticals; Histogen
- Class Amides; Aniline compounds; Anti-infectives; Antibacterials; Antifibrotics; Antihyperglycaemics; Antihypertensives; Antivirals; Fluorobenzenes; Hepatoprotectants; Pentanoic acids; Phenyl ethers; Small molecules
- Mechanism of Action Apoptosis inhibitors; Caspase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alcoholic hepatitis; COVID 2019 infections; Hepatic fibrosis; Liver disorders; Liver failure; Methicillin-resistant Staphylococcus aureus infections; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Portal hypertension; Septic shock; Skin and soft tissue infections; Type 1 diabetes mellitus
Most Recent Events
- 14 Dec 2023 Discontinued - Phase-I for COVID-2019 infections in USA (PO)
- 14 Dec 2023 Discontinued - Phase-I for Liver disorders in USA (IV)
- 14 Dec 2023 Discontinued - Phase-I/II for Type 1 diabetes mellitus in Canada (PO)